Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
MacroGenics
Scientific Title
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck